Endothelial Injury Biomarkers in Critical Illness Recovery

Abstract

Endothelial injury is a pivotal event in the pathophysiology of critical illnesses such as sepsis, acute respiratory distress syndrome (ARDS), and multi-organ dysfunction syndrome. Recent advancements have enhanced our understanding of endothelial dysfunction and the utility of specific biomarkers for assessing injury severity, predicting outcomes, and guiding therapeutic strategies in critically ill patients. This review synthesizes the latest evidence regarding key endothelial injury biomarkers, their mechanisms, clinical significance, and evolving roles in the management of critical illness recovery. Emphasis is placed on practical implications for clinicians and the potential of emerging biomarkers to transform post-ICU care trajectories.

Introduction

Endothelial cells line the vasculature and form a dynamic interface between circulating blood and tissues. Their integrity is essential for vascular tone regulation, permeability, and immune modulation. In critical illnesses, endothelial dysfunction and injury are common denominators contributing to disease progression, impaired organ perfusion, and poor outcomes. Biomarkers of endothelial injury provide valuable insights into disease mechanisms and patient prognosis, representing a rapidly evolving field of clinical investigation. This review explores current and emerging biomarkers, the pathophysiological underpinnings of endothelial injury in critical illness, and their clinical relevance in the recovery phase.

Epidemiology / Disease Burden

Critical illnesses such as sepsis, ARDS, and severe trauma affect millions worldwide annually, with high morbidity and mortality rates. Epidemiological studies underscore the centrality of endothelial dysfunction in the pathogenesis of organ failure, which remains a major determinant of ICU and post-ICU outcomes. Survivors of critical illness often experience prolonged endothelial dysfunction, contributing to persistent inflammation, organ dysfunction, and long-term mortality. The burden of disease necessitates reliable tools for risk stratification and monitoring, positioning endothelial biomarkers as essential components in modern critical care.

Pathophysiology

Endothelial injury in critical illness is multifactorial, involving direct pathogen-associated damage, dysregulated immune responses, and inflammatory cytokine release. Key mechanisms include increased endothelial permeability, leukocyte adhesion, disruption of intercellular junctions, and procoagulant shifts. These events precipitate capillary leak, tissue edema, and microvascular thrombosis. Biomarkers such as soluble thrombomodulin, angiopoietin-2, syndecan-1, and von Willebrand factor reflect distinct aspects of endothelial activation, glycocalyx shedding, and coagulopathy. Understanding these mechanisms is vital for interpreting biomarker dynamics and tailoring interventions.

Risk Factors

Risk factors for endothelial injury in the critically ill include advanced age, pre-existing cardiovascular or metabolic diseases, chronic kidney disease, and genetic predisposition. Acute triggers such as severe infection, systemic inflammation, hypoxia, and hypervolemia exacerbate endothelial vulnerability. Prolonged mechanical ventilation, vasopressor use, and exposure to nephrotoxic agents contribute to additional endothelial stress. Identifying these risk factors is crucial for early recognition of patients at highest risk for severe endothelial injury and poor recovery trajectories.

Clinical Features

Clinically, endothelial injury manifests as microvascular dysfunction, leading to tissue hypoperfusion, edema, and multi-organ dysfunction. In sepsis, this may present as hypotension, lactic acidosis, and coagulopathy. In ARDS, increased vascular permeability leads to pulmonary edema and refractory hypoxemia. Persistent endothelial activation is associated with impaired wound healing, prolonged ICU stays, and higher rates of readmission. Biomarker-guided assessment helps clinicians identify subclinical injury and anticipate complications.

Diagnosis

Diagnosis of endothelial injury is challenging due to the lack of specific clinical markers. Laboratory evaluation relies on measurement of circulating biomarkers such as soluble thrombomodulin, E-selectin, ICAM-1, VCAM-1, angiopoietin-2, syndecan-1, and von Willebrand factor. These biomarkers provide quantitative insights into endothelial activation, glycocalyx shedding, and prothrombotic states. Their serial measurement enables monitoring of disease progression and response to therapy. Integration with clinical scoring systems, such as the SOFA or APACHE II, enhances prognostication and facilitates individualized care plans.

Treatment & Management

Management of endothelial injury in critical illness is primarily supportive, focusing on early identification and treatment of the underlying cause (e.g., infection control in sepsis), hemodynamic optimization, and organ support. Interventions aimed at preserving endothelial integrity include judicious fluid management, minimizing exposure to harmful medications, and use of protective ventilation strategies. Experimental therapies targeting the endothelium, such as recombinant human thrombomodulin, antithrombin supplementation, and agents modulating the Ang-Tie2 axis, are under investigation for their potential to mitigate injury and improve outcomes.

Recent Advances / Emerging Therapies

Recent research has highlighted novel biomarkers, including cell-free DNA, microRNAs, and extracellular vesicles, as potential indicators of endothelial injury and repair capacity. High-throughput proteomic and metabolomic approaches are expanding the biomarker landscape, enabling more precise phenotyping of critical illness. Emerging therapies focus on restoring endothelial glycocalyx, stabilizing intercellular junctions, and modulating inflammatory signaling. Precision medicine approaches integrating biomarker panels with clinical data hold promise for personalized management and improved recovery in critically ill patients.

Guideline Recommendations

Current guidelines emphasize the importance of early recognition, aggressive management of underlying etiologies, and supportive care in patients with suspected endothelial injury. While routine use of endothelial biomarkers is not yet standardized, their incorporation into research protocols and specialized ICU settings is increasing. International consensus statements advocate for further validation of biomarker-guided approaches and integration into clinical practice, particularly for risk stratification and monitoring therapeutic responses.

Conclusion

Endothelial injury biomarkers represent an evolving frontier in critical care, offering valuable insights into disease mechanisms, prognosis, and therapeutic targeting. Their integration into clinical practice has the potential to enhance individualized care, improve outcomes, and reduce long-term morbidity in survivors of critical illness. Continued research and validation are essential to fully realize the clinical utility of these biomarkers and translate scientific advances into improved patient care.